1. Home
  2. CRON vs CMPX Comparison

CRON vs CMPX Comparison

Compare CRON & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cronos Group Inc.

CRON

Cronos Group Inc.

N/A

Current Price

$2.64

Market Cap

1.0B

Sector

Health Care

ML Signal

N/A

Logo Compass Therapeutics Inc.

CMPX

Compass Therapeutics Inc.

N/A

Current Price

$5.77

Market Cap

926.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CRON
CMPX
Founded
N/A
2014
Country
Canada
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
926.7M
IPO Year
2015
2020

Fundamental Metrics

Financial Performance
Metric
CRON
CMPX
Price
$2.64
$5.77
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
$14.43
AVG Volume (30 Days)
1.2M
1.8M
Earning Date
01-01-0001
03-31-2026
Dividend Yield
N/A
N/A
EPS Growth
157.89
N/A
EPS
N/A
N/A
Revenue
$117,615,000.00
$850,000.00
Revenue This Year
$18.81
N/A
Revenue Next Year
$34.20
N/A
P/E Ratio
N/A
N/A
Revenue Growth
34.82
N/A
52 Week Low
$1.60
$1.33
52 Week High
$3.43
$6.88

Technical Indicators

Market Signals
Indicator
CRON
CMPX
Relative Strength Index (RSI) 46.27 43.18
Support Level $2.44 $4.78
Resistance Level $2.77 $5.86
Average True Range (ATR) 0.08 0.31
MACD 0.01 -0.11
Stochastic Oscillator 21.70 6.54

Price Performance

Historical Comparison
CRON
CMPX

About CRON Cronos Group Inc.

Cronos Group Inc headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the U.S., the company has an option to acquire 5.9% of U.S. multistate operator PharmaCann on a fully diluted basis upon easing of federal prohibition.

About CMPX Compass Therapeutics Inc.

Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.

Share on Social Networks: